Page last updated: 2024-11-12
cylindrocyclophane a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cylindrocyclophane A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10348304 |
| CHEMBL ID | 1224866 |
| SCHEMBL ID | 16431175 |
| MeSH ID | M0397447 |
Synonyms (5)
| Synonym |
|---|
| CHEMBL1224866 |
| cylindrocyclophane a |
| SCHEMBL16431175 |
| (2r,3s,8s,13r,14s,19s)-8,19-dibutyl-3,14-dimethyltricyclo[18.2.2.29,12]hexacosa-1(22),9,11,20,23,25-hexaene-2,10,13,21,24,26-hexol |
| DTXSID301335544 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1289281 | Antibacterial activity against Klebsiella pneumoniae isolate 18 B224106 after 24 hrs | 2016 | Journal of natural products, Jan-22, Volume: 79, Issue:1 | Cylindrofridins A-C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale. |
| AID1289279 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 24 hrs | 2016 | Journal of natural products, Jan-22, Volume: 79, Issue:1 | Cylindrofridins A-C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale. |
| AID1289278 | Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 1 B690208 after 24 hrs | 2016 | Journal of natural products, Jan-22, Volume: 79, Issue:1 | Cylindrofridins A-C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale. |
| AID1289283 | Cytotoxicity against human HaCaT cells by Cell titre-blue assay | 2016 | Journal of natural products, Jan-22, Volume: 79, Issue:1 | Cylindrofridins A-C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale. |
| AID504304 | Cytotoxicity against human HT-29 cells | 2010 | Journal of natural products, Sep-24, Volume: 73, Issue:9 | Cylindrocyclophanes with proteasome inhibitory activity from the Cyanobacterium Nostoc sp. |
| AID1289280 | Antibacterial activity against Escherichia coli isolate 13 V676803 after 24 hrs | 2016 | Journal of natural products, Jan-22, Volume: 79, Issue:1 | Cylindrofridins A-C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale. |
| AID504303 | Inhibition of 20S proteasome | 2010 | Journal of natural products, Sep-24, Volume: 73, Issue:9 | Cylindrocyclophanes with proteasome inhibitory activity from the Cyanobacterium Nostoc sp. |
| AID1289282 | Antibacterial activity against Pseudomonas aeruginosa isolate 22 V143708 after 24 hrs | 2016 | Journal of natural products, Jan-22, Volume: 79, Issue:1 | Cylindrofridins A-C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||